The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Open accessAbstract
Several cancers are highly refractory to conventional chemotherapy. The survival of tumors in several cases is assisted by checkpoint immunomodulation to maintain the imbalance between immune surveillance and cancer cell proliferation. Check point antibody inhibitors, such as anti-PD-1/PD-L1, are a novel class of inhibitors that function as a tumor suppressing factor via modulation of immune cell-tumor cell interaction. These checkpoint blockers are rapidly becoming a highly promising cancer therapeutic approach that yields remarkable antitumor responses with limited side effects. In recent times, more than four check point antibody inhibitors have been commercialized for targeting PD-1, PDL-1, and CTLA-4. Despite the huge success and efficacy of the anti-PD therapy response, it is limited to specific types of cancers, which attributes to the insufficient and heterogeneous expression of PD-1 in the tumor microenvironment. Herein, we review the current landscape of the PD-1/PD-L1 mechanistic role in tumor immune evasion and therapeutic outcome for cancer treatment. We also review the current progress in clinical trials, combination of drug therapy with immunotherapy, safety, and future of check point inhibitors for multiple types of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
Immune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,709
The PD‐1 pathway in tolerance and autoimmunity
Francisco, L. M., Sage, P. T., & Sharpe, A. H. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00923.x · Cited by 2,300
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127
Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H., & Freeman, G. J. (2007) · Immunity · doi:10.1016/j.immuni.2007.05.016 · Cited by 1,732
Inhibitory B7-family molecules in the tumour microenvironment
Zou, W., & Chen, L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2326 · Cited by 1,608
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes
Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubat, T., Yagita, H., & Honjo, T. (1996) · International Immunology · doi:10.1093/intimm/8.5.765 · Cited by 1,589
Cancer Research Communications
(2021) · doi:10.1158/1078-0432 · Cited by 1,532
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv383 · Cited by 1,470
Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
Chen, L., & Han, X. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80011 · Cited by 1,437
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.12.009 · Cited by 1,329
Combination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294
Immunological hallmarks of stromal cells in the tumour microenvironment
Turley, S. J., Cremasco, V., & Astarita, J. L. (2015) · Nature Reviews Immunology · doi:10.1038/nri3902 · Cited by 1,140
Roland, L., Grau, M., Matena, J., Teske, M., Gieseke, M., Kampmann, A., Beyerbach, M., Murua Escobar, H., Haferkamp, H., Gellrich, N.-C., et al. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms17010001 · Cited by 862
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
Ohaegbulam, K. C., Assal, A., Lazar-Molnar, E., Yao, Y., & Zang, X. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.10.009 · Cited by 843
Ott, P. A., Hodi, F. S., & Robert, C. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0143 · Cited by 696
Berger, R., Rotem-Yehudar, R., Slama, G., Landes, S., Kneller, A., Leiba, M., Koren-Michowitz, M., Shimoni, A., & Nagler, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4079 · Cited by 680
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
Wilmott, J. S., Long, G. V., Howle, J. R., Haydu, L. E., Sharma, R. N., Thompson, J. F., Kefford, R. F., Hersey, P., & Scolyer, R. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2479 · Cited by 652
Adaptive Immune Resistance: How Cancer Protects from Immune Attack
Ribas, A. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0563 · Cited by 613
Antonia, S., Goldberg, S. B., Balmanoukian, A., Chaft, J. E., Sanborn, R. E., Gupta, A., Narwal, R., Steele, K., Gu, Y., Karakunnel, J. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00544-6 · Cited by 602
PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
D'Incecco, A., Andreozzi, M., Ludovini, V, Rossi, E., Capodanno, A., Landi, L., Tibaldi, C., Minuti, G., Salvini, J., Coppi, E., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2014.555 · Cited by 593
Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
Lipson, E. J., & Drake, C. G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1595 · Cited by 570
Slovin, S. F., Higano, C. S., Hamid, O., Tejwani, S., Harzstark, A., Alumkal, J. J., Scher, H. I., Chin, K., Gagnier, P., McHenry, M. B., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt107 · Cited by 559
McDermott, D. F., Sosman, J. A., Sznol, M., Massard, C., Gordon, M. S., Hamid, O., Powderly, J. D., Infante, J. R., Fassò, M., Wang, Y. V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.7421 · Cited by 557
Westin, J. R., Chu, F., Zhang, M., Fayad, L. E., Kwak, L. W., Fowler, N., Romaguera, J., Hagemeister, F., Fanale, M., Samaniego, F., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70551-5 · Cited by 529
Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer—Response
Sznol, M., & Chen, L. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2234 · Cited by 528
Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer
Sznol, M., & Chen, L. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2063 · Cited by 488
Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment
Gajewski, T. F., Woo, S.-R., Zha, Y., Spaapen, R., Zheng, Y., Corrales, L., & Spranger, S. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.02.009 · Cited by 422
Wang, D., Wang, T., Liu, J., Yu, H., Jiao, S., Feng, B., Zhou, F., Fu, Y., Yin, Q., Zhang, P., et al. (2016) · Nano Letters · doi:10.1021/acs.nanolett.6b01994 · Cited by 405
PD-1 is a novel regulator of human B-cell activation
Thibult, M.-L., Mamessier, E., Gertner-Dardenne, J., Pastor, S., Just-Landi, S., Xerri, L., Chetaille, B., & Olive, D. (2013) · International Immunology · doi:10.1093/intimm/dxs098 · Cited by 365
Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies
Philips, G. K., & Atkins, M. (2015) · International Immunology · doi:10.1093/intimm/dxu095 · Cited by 335
Xiao, Y., Yu, S., Zhu, B., Bedoret, D., Bu, X., Francisco, L. M., Hua, P., Duke-Cohan, J. S., Umetsu, D. T., Sharpe, A. H., et al. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20130790 · Cited by 321
Immune Activation by Bacterial DNA: A New Genetic Code
Pisetsky, D. S. (1996) · Immunity · doi:10.1016/s1074-7613(00)80256-3 · Cited by 298
CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
Callahan, M. K., Postow, M. A., & Wolchok, J. D. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2014.00385 · Cited by 224
IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells
Sun, Z., Fourcade, J., Pagliano, O., Chauvin, J.-M., Sander, C., Kirkwood, J. M., & Zarour, H. M. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3016 · Cited by 198
Enhanced T-Cell Immunity to Osteosarcoma Through Antibody Blockade of PD-1/PD-L1 Interactions
Lussier, D. M., O’Neill, L., Nieves, L. M., McAfee, M. S., Holechek, S. A., Collins, A. W., Dickman, P., Jacobsen, J., Hingorani, P., & Blattman, J. N. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000065 · Cited by 197
Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance
Martin, A. M., Nirschl, T. R., Nirschl, C. J., Francica, B. J., Kochel, C. M., van Bokhoven, A., Meeker, A. K., Lucia, M. S., Anders, R. A., DeMarzo, A. M., et al. (2015) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2015.39 · Cited by 188
Hazarika, M., Chuk, M. K., Theoret, M. R., Mushti, S., He, K., Weis, S. L., Putman, A. H., Helms, W. S., Cao, X., Li, H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0712 · Cited by 183
Barbee, M. S., Ogunniyi, A., Horvat, T. Z., & Dang, T.-O. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015586218 · Cited by 179
Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities
Morrissey, K., Yuraszeck, T., Li, C., Zhang, Y., & Kasichayanula, S. (2016) · Clinical and Translational Science · doi:10.1111/cts.12391 · Cited by 171
Aguiar, P. N., Santoro, I. L., Tadokoro, H., de Lima Lopes, G., Filardi, B. A., Oliveira, P., Mountzios, G., & de Mello, R. A. (2016) · Immunotherapy · doi:10.2217/imt-2015-0002 · Cited by 160
Sondak, V. K., Smalley, K. S. M., Kudchadkar, R. R., Grippon, S., & Kirkpatrick, P. N. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3463 · Cited by 158
Li, Y., Li, F., Jiang, F., Lv, X., Zhang, R., Lü, A., & Zhang, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17071151 · Cited by 154
Luong, D., Kesharwani, P., Alsaab, H. O., Sau, S., Padhyé, S., Sarkar, F. H., & Iyer, A. K. (2017) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2017.06.025 · Cited by 113
Self-citationGettinger, S. N., Shepherd, F. A., Antonia, S. J., Brahmer, J. R., Chow, L. Q. M., Juergens, R. A., Borghaei, H., Shen, Y., Harbison, C. T., Alaparthy, S., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8024 · Cited by 104
Azijli, K., Stelloo, E., Peters, G. J., & van den Eertwegh, A. J. M. (2014) · PubMed · Cited by 99
EZH2 as a potential target in cancer therapy
McCabe, M. T., & Creasy, C. L. (2014) · Epigenomics · doi:10.2217/epi.14.23 · Cited by 93
Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy
Spranger, S., Sivan, A., Corrales, L. P., & Gajewski, T. F. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.003 · Cited by 88
pH responsive biodegradable nanogels for sustained release of bleomycin
Sahu, P. K., Kashaw, S. K., Kushwah, V., Sau, S., Jain, S., & Iyer, A. K. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.06.038 · Cited by 85
Self-citationCombining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma.
Kim, T. S., Amaria, R. N., Spencer, C. N., Reuben, A., Cooper, Z. A., & Wargo, J. A. (2014) · PubMed Central · doi:10.7497/j.issn.2095-3941.2014.04.002 · Cited by 77
Gawde, K. A., Kesharwani, P., Sau, S., Sarkar, F. H., Padhyé, S., Kashaw, S. K., & Iyer, A. K. (2017) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2017.01.092 · Cited by 70
Self-citationPhase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma.
Atkins, M. B., Kudchadkar, R. R., Sznol, M., McDermott, D. F., Lotem, M., Schachter, J., Wolchok, J. D., Urba, W. J., Kuzel, T. M., Schuchter, L. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.9001 · Cited by 65
Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis
Pasquali, S., Chiarion‐Sileni, V., Rossi, C. R., & D, S. M. M. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.01.006 · Cited by 61
Folate decorated nanomicelles loaded with a potent curcumin analogue for targeting retinoblastoma
Alsaab, H., Alzhrani, R., Kesharwani, P., Sau, S., Boddu, S., & Iyer, A. (2017) · Pharmaceutics · doi:10.3390/pharmaceutics9020015 · Cited by 46 · cited 1×
“Various types of nanoparticles have been utilized for cancer drug delivery (Sau et al., 2014; Alsaab et al., 2017; Gawde et al., 2017; Luong et al., 2017; Sahu et al., 2017) and current research outcomes are coming out to target the immune check point inhibitors for cancer therapy (Wang et al.”
BackgroundSau, S., Mondal, S. K., Kashaw, S. K., Iyer, A. K., & Banerjee, R. (2017) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-017-3084-z · Cited by 39
Self-citationRizvi, N. A., Chaft, J. E., Balmanoukian, A. S., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-3-s2-p193 · Cited by 20
Cited by
Delivery technologies for cancer immunotherapy
Riley, R. S., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,607
Three-dimensional in vitro cell culture models in drug discovery and drug repositioning
Langhans, S. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00006 · Cited by 1,522
CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy
Barkal, A. A., Brewer, R. E., Markovic, M., Kowarsky, M., Barkal, S. A., Zaro, B. W., Krishnan, V., Hatakeyama, J., Dorigo, O., Barkal, L. J., et al. (2019) · Nature · doi:10.1038/s41586-019-1456-0 · Cited by 1,385
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
Yi, M., Jiao, D., Xu, H., Liu, Q., Zhao, W., Han, X., & Wu, K. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0864-3 · Cited by 764
The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications
Linehan, W. M., & Ricketts, C. J. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0211-5 · Cited by 621
Metadata
- Authors
- Alsaab, H. O., Sau, S., Alzhrani, R., Tatiparti, K., Bhise, K., Kashaw, S. K., & Iyer, A. K.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2017-08-23
- Volume
- 8
- Pages
- 561-561
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2747016053
- Cited by
- 1,707
- References
- 70
- FWCI
- 62.47
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.